spacer
home > ebr > summer 2018 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

EBR: What are the benefits of mass spectrometry (MS) as an analytical method?

Simon Cubbon: MS, from its early beginnings through to its current use, has seen an ever-increasing adoption; this is because of the large amounts of information, resulting in quality and, therefore, confidence that this technique can provide, ultimately, safeguarding end-users.

Additionally, both high- and low-resolution systems are becoming increasingly simpler to use; this, combined with the intricacy of products being brought to market (eg protein-based therapeutics, such as monoclonal antibodies or antibodydrug conjugates), requires techniques that can provide the necessary structural insights needed to fully characterise and understand these complexities.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Simon Cubbon works as a pharma and biopharmaceutical Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he was interested in using LC-MS to study the metabolic profile of long bone fractures.
spacer
Dr Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo includes Sheremetyevo Airport near Moscow to its cargo flights network.

As the fastest growing brand among the global air cargo carriers with its extensive flights network, Turkish Cargo included Sheremetyevo Airport (SVO), known as being the most important airport in Russia in terms of cargo activities, to its direct cargo flight destinations network.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement